Aerie Pharma (AERI) Receives a Buy from Needham

Needham analyst Serge Belanger assigned a Buy rating to Aerie Pharma (AERIResearch Report) today and set a price target of $26.00. The company’s shares closed last Friday at $17.94.

According to, Belanger is a 4-star analyst with an average return of 8.3% and a 48.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $27.25 average price target, representing a 53.6% upside. In a report issued on April 9, Mizuho Securities also maintained a Buy rating on the stock with a $28.00 price target.

See today’s analyst top recommended stocks >>

Aerie Pharma’s market cap is currently $809.3M and has a P/E ratio of -4.40. The company has a Price to Book ratio of 34.16.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.